Historical Perspective
Acute activation of G␣ i/o -coupled receptors inhibits cAMP accumulation, whereas prolonged activation enhances drugstimulated cAMP accumulation. This enhanced responsiveness was first observed following persistent activation of the -opioid receptor in the laboratory of Dr. Marshall Nirenberg (National Institute of Mental Health, Bethesda, MD), who proposed that the increased responsiveness was a mechanism of opiate tolerance and dependence (Sharma et al., 1975) . This phenomenon has since been described using many different names, including cAMP overshoot, supersensitivity, superactivation, supersensitization, and heterologous sensitization of adenylate cyclase (EC 4.6.1.1).
1 The term heterologous sensitization will be used throughout this article to describe observations where persistent activation of a G␣ i/o -coupled receptor induces an enhanced response to drug-stimulated cAMP accumulation (Fig. 1 ). Those initial observations from the Nirenberg laboratory (Sharma et al., 1975) prompted a number of subsequent investigations aimed at determining the receptor and tissue specificity of heterologous sensitization and identifying the molecular mechanisms responsible for this phenomenon. These studies revealed that persistent activation of several G␣ i/o -coupled receptors (including opioid, ␣ 2 -adrenergic, adenosine, somatostatin, and muscarinic receptors) induces heterologous sensitization in both neuronal and non-neuronal cellular models (see review by Thomas and Hoffman, 1987) . Based on the results from these studies, Thomas and Hoffman (1987) proposed the following model: chronic agonist stimulation of a G␣ i -coupled receptor induces heterologous sensitization through a pertussis toxin-sensitive G protein, invoking an unknown mechanism that may ultimately alter G␣ s , G␣ i , or adenylate cyclase to contribute to the enhanced cAMP response. Furthermore, this mechanism does not involve desensitization or tolerance of the G␣ i -coupled receptor, and the This work was supported by the National Institute of Mental Health, MH60397, the National Alliance for Research on Schizophrenia and Depression, and Purdue University.
1 I have used adenylate cyclase as the common name of the enzyme EC 4.6.1.1 based on the recommendation of the International Union of Biochemistry and Molecular Biology (IUBMB) (http://www.chem.qmw.ac.uk/iubmb/enzyme/EC4/6/1/1.html). Other sources that list adenylate cyclase as the preferred common name include Dorland's Medical Dictionary, the Sourcebook of Enzymes by White and White, Stedman's Medical Dictionary (27th edition) , and the Oxford Dictionary of Biochemistry and Molecular Biology. precise role of cAMP inhibition is unknown (Thomas and Hoffman, 1987) .
Although the general characteristics of heterologous sensitization proposed by Thomas and Hoffman (1987) are consistent with more recent studies of G␣ i/o -coupled receptors, a number of advances have provided additional information regarding the molecular mechanisms of heterologous sensitization using a variety of cellular models. The cloning and biochemical characterization of the nine membrane-bound adenylate cyclase isoforms has revealed that different isoforms have distinct regulatory properties (Taussig and Zimmerman, 1998) . Several research groups have sought to exploit the differences among isoforms to identify mechanisms of heterologous sensitization, and the results of their studies suggest that sensitization is isoform-dependent so that the characteristics of heterologous sensitization in a given cell depend on the complement of adenylate cyclase isoforms present in the cell (Thomas and Hoffman, 1996; Watts and Neve, 1996; Avidor-Reiss et al., 1997; Cumbay and Watts, 2001) . In the present article, the mechanisms of heterologous sensitization in neuronal and non-neuronal cultured cells will be discussed as they relate to the early (development) and the late (expression) events associated with heterologous sensitization (Fig. 1) . The development of heterologous sensitization will refer to events that are more closely associated with the persistent stimulation of the G␣ i/o -coupled receptor (e.g., activation of G␣ i/o proteins). The expression of heterologous sensitization will refer to events that influence cAMP accumulation in response to G␣ s -coupled receptor agonists, forskolin (a direct activator of adenylate cyclase), or selective activators of adenylate cyclase isoforms . Studies over the last 15 years have focused on the mechanisms involved in the development of heterologous sensitization, and more recent studies have identified potential mechanisms specifically involved in the expression of heterologous sensitization. Although the present article will often focus on heterologous sensitization following persistent stimulation of the D 2 dopamine receptor (Fig. 2) , it is likely that the mechanisms associated with one G␣ i/o -coupled receptor are similar to those associated with other G␣ i/o -coupled receptors, including -opioid, CB 1 cannabinoid, ␣ 2 adrenergic, M 2 and M 4 muscarinic, A 3 adenosine, and 5-hydroxytryptamine 1A serotonin receptors (Avidor-Reiss et al., 1995; Hensler et al., 1996; Thomas and Hoffman, 1996; Palmer et al., 1997; Nevo et al., 1998; Rhee et al., 2000) .
G Protein ␣ Subunit Specificity for Heterologous Sensitization
Pertussis toxin treatment prevents heterologous sensitization of both endogenous and recombinant adenylate cyclases in several cellular models (Watts and Neve, 1996; Palmer et al., 1997; Watts et al., 1998 Watts et al., , 1999 Rhee et al., 2000; Rubenzik et al., 2001) . Because pertussis toxin prevents receptor coupling to G␣ i1 , G␣ i2 , G␣ i3 , and G␣ o in a nondiscriminating fashion, one important question is which pertussis toxinsensitive G protein is responsible for heterologous sensitization. This question has been investigated for D 2L dopamine receptors and several of the opioid receptors (Watts et al., 1998; Tso and Wong, 2000; Tso and Wong, 2001 ). The D 2L dopamine receptor study used viral-mediated gene delivery of individual genetically engineered pertussis toxin-resistant G proteins (G␣ x *) to determine the G protein specificity for heterologous sensitization in NS20Y neuroblastoma cells (Watts et al., 1998) . These experiments examined the ability of individual recombinant ␣ subunits G␣ x * to rescue heterologous sensitization in pertussis toxin-treated cells. Selective activation of G␣ o * by D 2L receptors was found to be responsible for heterologous sensitization of forskolin-stimulated cAMP accumulation in NS20Y-D 2L cells. In contrast, expression of mutant G␣ i1 *, G␣ i2 *, and G␣ i3 * subunits did not rescue heterologous sensitization in pertussis toxintreated cells. Similar studies in pertussis toxin-treated human embryonic kidney-D 2L cells revealed that heterologous dopamine receptors promotes the dissociation of G␣ and ␤␥ subunits in a pertussis toxin-sensitive matter, which in turn, induces sensitization through a G␣ s -dependent mechanism. The signaling events that follow the activation of the G␣ i/o subunits and the release of the ␤␥ subunits (represented by a ? in the black box) are thought to produce an enhanced interaction between G␣ s and adenylate cyclase (represented by green outline around G␣ s ). These drug-induced changes enhance cAMP accumulation that can be observed following stimulation of adenylate cyclase with forskolin or using isoproterenol (Iso) to stimulate the ␤ 1 adrenergic receptor (G␣ s pathway).
sensitization is rescued by the expression of either G␣ o * or G␣ i1 * (B. L. Wiens, V. J. Watts, and K. A. Neve, unpublished results). The abundant expression of G␣ o throughout the central nervous system and recent studies demonstrating that D 2 dopamine receptors couple efficiently to G␣ o in native brain tissue suggest an important role for G␣ o in heterologous sensitization (Jiang et al., 2001) .
Heterologous sensitization may also involve the simultaneous activation of multiple G␣ i/o proteins. For example, the magnitude of selective G␣ o *-induced heterologous sensitization seems to be reduced when compared with sensitization in cells where the entire endogenous G␣ i/o pool was available (Watts et al., 1998) . In fact, a role for multiple G␣ subunits has been proposed for opioid-induced heterologous sensitization because the expression of G␣ i1 * only partially rescues ␦-opioid receptor-induced sensitization, whereas expression of G␣ i3 * or a pertussis toxin-insensitive G␣ i2/z * chimera has no effect Wong, 2000, 2001) . Furthermore, the expression of G␣ i1 *, G␣ i3 *, or a pertussis toxin-insensitive G␣ i2/z * fails to rescue -or -opioid receptor-induced sensitization Wong, 2000, 2001) . Although the importance of G␣ o in opioid receptor-induced heterologous sensitization has not been examined, these results would be consistent with the contribution of multiple G␣ subunits to sensitization. In addition, it is also possible that the specificity among G␣ i/o subtypes for heterologous sensitization is governed by receptor/G protein coupling. In other words, all pertussis toxin-sensitive G proteins may have the ability to induce heterologous sensitization if activated sufficiently by a receptor.
G Protein ␣ Subunit Expression and Heterologous Sensitization
It has been proposed that persistent activation of G␣ i/o induces heterologous sensitization through changes in the abundance of G␣ s and G␣ i/o. In some studies, chronic activation of G␣ i/o -coupled receptors results in reduced levels of G␣ i/o or increased levels of G␣ s (Hadcock and Malbon, 1993; Watts et al., 1999) , either of which would be predicted to enhance subsequent adenylate cyclase activity. In contrast, other studies have demonstrated that alterations in the abundance of G␣ i/o or G␣ s are not required for heterologous sensitization of adenylate cyclase (Palmer et al., 1997; Watts et al., 1999; Bayewitch et al., 2000) . The ability of agonist treatment to induce changes in G␣ i/o or G␣ s levels seems to be dependent on the cellular model or cell line under investigation. Furthermore, the magnitude of and time course for changes in G␣ i/o or G␣ s do not seem to correlate directly with measures of heterologous sensitization. For example, heterologous sensitization can be observed within 15 min of agonist treatment (Thomas and Hoffman, 1996; Watts and Neve, 1996; Jones et al., 1987) , and robust sensitization is commonly observed following 2 to 4 h of drug treatment (AvidorReiss et al., 1995; Watts and Neve, 1996; Palmer et al., 1997; Nevo et al., 1998; Cumbay and Watts, 2001; Watts et al., 2001) . In contrast, agonist-induced changes in G␣ levels, which probably involve changes in gene expression, typically require long-term receptor activation (Hadcock and Malbon, 1993; Watts et al., 1999) . Together, these observations suggest that, although agonist-induced changes in G␣ i/o or G␣ s levels are not required for the development of heterologous sensitization, they may influence the magnitude or expression of heterologous sensitization.
It is also possible that heterologous sensitization could involve a change in the localization of G proteins, as opposed to a change in overall protein levels. For example, persistent agonist treatment of -opioid receptors decreases the detergent solubility (and presumably lipid microdomain localization) of G␣ i and the ␤ 1 subunit . These changes occur rapidly (Ͻ4 h) and correlate with agonistinduced heterologous sensitization of adenylate cyclase. Similar agonist-induced changes in the detergent solubility of G␣ i and ␤ 1 were also observed in cells expressing -opioid and M 4 muscarinic receptors. Additional studies are necessary to determine the precise role that these changes play in both the development and expression of heterologous sensitization.
G Protein ␤␥ Subunits and Heterologous Sensitization
The activation of G␣ i/o -coupled receptors results in the dissociation of activated G␣ and ␤␥ subunits. The released ␤␥ subunits directly modulate a number of cellular effectors, including several isoforms of adenylate cyclase Taussig and Zimmerman, 1998) . That both the release of ␤␥ subunits and heterologous sensitization occur in a pertussis toxin-sensitive manner may suggest a potential relationship. More direct evidence to support a role for ␤␥ subunits in heterologous sensitization was obtained using recombinant proteins capable of binding ␤␥ subunits, such as the C-terminus of GRK2 (␤ARK-Ct) or G␣ t (Avidor-Reiss et al., 1996; Thomas and Hoffman, 1996) . This approach is based on the tenet that overexpression of a ␤␥-binding protein prevents downstream ␤␥ subunit signaling by scavenging free ␤␥ subunits. Expression of these ␤␥ subunit scavengers attenuates or prevents the development of heterologous sensitization following the activation of -opioid, CB 1 cannabinoid, and D 2 dopamine receptors in cultured cell systems (Avidor-Reiss et al., 1996; Thomas and Hoffman, 1996; Rhee et al., 2000; Rubenzik et al., 2001) .
The simplest explanation for these results is that prolonged activation of G␣ i/o liberates ␤␥ subunits that directly activate and sensitize adenylate cyclase. However, this mechanism is unlikely for several reasons. First, the persistence of the sensitized response following removal of the G␣ i/ocoupled receptor agonist (Ն1 h) is inconsistent with a transient increase in free ␤␥ subunits (Watts and Neve, 1996) . Second, adenylate cyclase isoforms capable of undergoing heterologous sensitization (Table 1) show markedly different patterns of regulation by ␤␥ subunits Nevo et al., 1998; Taussig and Zimmerman, 1998; Cumbay and Watts, 2001 ). For example, both AC1 and AC2 are sensitized by persistent D 2L receptor activation (Watts and Neve, 1996; Cumbay and Watts, 2001) , although ␤␥ subunits inhibit AC1 activity and conditionally stimulate AC2 activity (Taussig and Zimmerman, 1998) . In addition, AC3, AC8, and AC9 exhibit heterologous sensitization even though they are relatively insensitive to ␤␥ subunits (Avidor-Reiss et al., 1997; Rhee et al., 2000; Cumbay and Watts, 2001) . The complexity of the ␤␥ subunit regulatory effects is also evident from studies examining the effects of ␤␥ subunits on the activity of AC5 and AC6. Sequestering ␤␥ subunits enhances Heterologous Sensitization of Adenylate Cyclase drug-stimulated activity of AC5 but prevents the development of agonist-induced sensitization of both AC5 and AC6 (Avidor-Reiss et al., 1996; Thomas and Hoffman, 1996; Bayewitch et al., 1998; Rhee et al., 2000; Rubenzik et al., 2001 ). These observations suggest that the effects of ␤␥ subunits on the expression of heterologous sensitization are complex and may be isoform-dependent. Nevertheless, the data demonstrating that both ␤␥ subunit scavengers and pertussis toxin treatment prevent heterologous sensitization provide evidence of an important role for the liberation of ␤␥ subunits in the development of sensitization.
Role of cAMP Accumulation and PKA in Heterologous Sensitization
Although acute activation of G␣ i/o -coupled receptors can modulate a number of signaling pathways, inhibition of drugstimulated cAMP accumulation is often considered the defining physiological response. Inhibition of cAMP formation decreases PKA activity and inhibits subsequent PKA-mediated phosphorylation events. The role of PKA inhibition in G␣ i/ocoupled receptor-induced sensitization has been addressed by manipulating both intracellular cAMP levels and PKA activity, with results suggesting that inhibition of cAMP and PKA is not generally required for heterologous sensitization (Thomas and Hoffman, 1992; Avidor-Reiss et al., 1995; Watts and Neve, 1996; Watts et al., 1999; Johnston et al., 2001) . In contrast, a role for PKA in heterologous sensitization was observed in one study in which somatostatin treatment induced sensitization in wild-type S49 cells but not in the PKA-deficient kin Ϫ S49 cells (Thomas and Hoffman, 1989 ).
Another study showed that PKA activators prevent A 1 adenosine receptor-induced heterologous sensitization in DDT 1 -MF-2 cells (Port et al., 1992) . Results from recent studies in our laboratory demonstrated that chronic inhibition of PKA induced heterologous sensitization in a novel neuronal cell line, Cath.a. differentiated (CAD)-D 2L cells, and that activators of PKA attenuated sensitization (Johnston et al., 2002) . Thus, although inhibition of cAMP and PKA is not generally required for the development or expression of heterologous sensitization, inhibition of PKA may contribute to the development of sensitization in select cellular models.
Adenylate Cyclase Isoform Specificity and Heterologous Sensitization
A number of studies have provided evidence that agonistinduced sensitization is influenced by the complement of endogenous or recombinant adenylate cyclase isoforms present within the cell (Thomas and Hoffman, 1996; Watts and Neve, 1996; Avidor-Reiss et al., 1997; Rhee et al., 2000; Cumbay and Watts, 2001 ). The basic features associated with heterologous sensitization of the recombinant isoforms of adenylate cyclase parallel those characteristics described for studies of the endogenous isoforms of adenylate cyclase. In addition, a few distinct patterns have been observed for the recombinant adenylate cyclases (Table 1) 
(ϩ), increased response; (Ϫ), reduced response, (no), no effect; Ca 2ϩ , ionomycin/A23187; FSK, forskolin; G␣ s , activation of G␣ s -coupled receptor; PKC, phorbol, 12-myristate, 13-acetate.
a Conditionally stimulated by ␤␥ subunits in presence of activated G␣ s . b Watts and Neve (1996) . c Thomas and Hoffman (1996) . d Avidor-Reiss et al. (1997) . e Nevo et al. (1998) . f Rhee et al. (2000) . g Nevo et al. (2000) . h Cumbay and Watts (2001) . jpet.aspetjournals.org Watts et al., 2001) . Persistent agonist treatment also causes sensitization of Ca 2ϩ -stimulated AC1 and AC8 activity (Avidor-Reiss et al., 1997; Nevo et al., 1998; Cumbay and Watts, 2001) . In contrast to AC1 and AC8, the remaining Ca 2ϩ -stimulated isoform AC3 does not show robust sensitization to calcium ionophores or G␣ s (Avidor-Reiss et al., 1997; , although sensitization to forskolin has been reported (Rhee et al., 2000) . AC2, AC4, and AC7, which are conditionally activated by ␤␥ subunits, show a unique pattern of heterologous sensitization. Specifically, it was observed that these isoforms of adenylate cyclase either show no sensitization or have a reduced responsiveness to G␣ sstimulated cAMP accumulation following agonist treatment (Thomas and Hoffman, 1996; Avidor-Reiss et al., 1997; Nevo et al., 1998; Nevo et al., 2000; Rhee et al., 2000; Cumbay and Watts, 2001 ). In contrast, protein kinase C-stimulated AC2 activity is robustly sensitized by persistent activation of D 2 dopamine receptors (Watts and Neve, 1996; Cumbay and Watts, 2001 ). At present, the reasons for the small disparities between laboratories are unclear but may be due to differences in the G␣ i/o -coupled receptors, the cell type, transfection methodology (stable versus transient), the method used to assess adenylate cyclase activity, or other variations in laboratory procedures (Table 1) . Although the preponderance of evidence indicates that most isoforms are capable of undergoing sensitization, that each isoform (or family of isoforms) shows distinctive patterns of G␣ s activation in the presence of other adenylate cyclase regulators is an important factor in the observed cAMP response (Harry et al., 1997; Taussig and Zimmerman, 1998) . Moreover, the response to G␣ s and the unique regulatory properties of each isoform are likely to influence the expression, but not the development, of heterologous sensitization of each adenylate cyclase isoform following persistent G␣ i/o -coupled receptor activation.
Role of G␣ s in Heterologous Sensitization
In spite of their differential regulation, all isoforms of adenylate cyclase are activated by G␣ s (Taussig and Zimmerman, 1998) , and several observations support the hypothesis that the mechanisms underlying heterologous sensitization involve enhanced G␣ s activity or enhanced G␣ s /adenylate cyclase interactions. Jones and Bylund (1990) demonstrated that sensitization of adenylate cyclase is associated with an increase in [ 3 H]forskolin binding that may represent the formation of G␣ s -adenylate cyclase complexes. Studies in C6 glioma cells expressing the D 2L dopamine receptor revealed that agonist treatment increases the potency of forskolin and enhances the maximal responsiveness of adenylate cyclase to the ␤-adrenergic receptor agonist isoproterenol, consistent with the effects of increased G␣ s activity on adenylate cyclase (Watts and Neve, 1996) . Furthermore, isoforms of adenylate cyclase that are activated synergistically by G␣ s together with isoform-selective activators (i.e., AC1, Ca 2ϩ ; AC2, phorbol esters; AC5, 100 nM forskolin) also show a marked degree of short-term (2 h) sensitization (Watts and Neve, 1996; Taussig and Zimmerman, 1998; Cumbay and Watts, 2001; Watts et al., 2001 ). These findings suggest that AC1, AC2, and AC5 may share an overlapping mechanism of heterologous sensitization that seems to be dependent upon a synergistic response to selective activators and G␣ s . Although these observations provide important evidence that G␣ s is involved in heterologous sensitization of adenylate cyclase, the precise role for G␣ s is unknown.
Confirmation of a direct role for G␣ s in heterologous sensitization is a difficult task because biochemical and molecular reagents specifically inhibiting G␣ s function are not readily available. In light of such limitations, a novel approach to examine the role of G␣ s in heterologous sensitization has recently been developed . We hypothesized that if G␣ s is required for expression of sensitization, mutants of adenylate cyclase that are not activated by G␣ s should not be sensitized following G␣ i/o receptor activation. This hypothesis was tested using viral-mediated gene delivery of G␣ s -insensitive mutants of AC5 to examine D 2L dopamine receptor-induced heterologous sensitization . We observed that persistent activation of the D 2 dopamine receptor failed to sensitize each of the three G␣ s -insensitive mutants of AC5, whereas, the wild-type AC5 showed a marked degree of heterologous sensitization. These results indicate that activation of adenylate cyclase by G␣ s is required for the expression of heterologous sensitization of adenylate cyclase.
The mechanisms responsible for the altered activity of G␣ s or an enhanced interaction between G␣ s and adenylate cyclase that contribute to heterologous sensitization remain unclear. One possibility is that heterologous sensitization may involve a post-translational modification of G␣ s that alters membrane localization. For example, morphine-induced heterologous sensitization has been associated with a reduction in the amount of palmitoylated G␣ s and presumably membrane-associated G␣ s which may, in turn, enhance the interaction of G␣ s with adenylate cyclase (Ammer and Schulz, 1997) . Enhanced interactions of G␣ s and adenylate cyclase have been associated with an increase in the proportion of G␣ s that can be extracted from the membranes with Triton X-100 and a decrease in the abundance of G␣ s in caveolin-enriched domains (Toki et al., 1999; Miura et al., 2001) . In contrast, colocalization of both G␣ s -coupled receptors and AC6 to caveolin-enriched domains enhances coupling efficiency and drug-stimulated cAMP accumulation (Ostrom et al., 2001) . Although a role for caveolae in heterologous sensitization has not been established, future studies should explore the effects of persistent activation of G␣ i/ocoupled receptors on the subcellular localization of G␣ s and adenylate cyclases. The observations described above implicate a role for G␣ s in heterologous sensitization in cellular models; however, recent studies have suggested that an additional stimulatory G protein, G␣ olf , is also an important regulator of adenylate cyclase activity (Corvol et al., 2001 ).
Relevance of Heterologous Sensitization to Drug Abuse
It is well established that chronic administration of opiates and other drugs of abuse induces an up-regulation of the cAMP signaling pathway in several brain regions (Nestler, 2001) . Although abused drugs have a variety of acute mechanisms of action, many of the drugs ultimately lead to persistent activation of G␣ i/o -coupled receptors. For example, morphine acts directly on G␣ i/o -coupled -opioid receptors in the locus coeruleus, with chronic treatment leading to enhanced (sensitized) adenylate cyclase activity (Nestler, Heterologous Sensitization of Adenylate Cyclase 2001). Similarly, chronic cocaine treatment increases adenylate cyclase activity in the nucleus accumbens, presumably through its actions on dopamine release in the mesolimbic reward pathway, which would be expected to increase activation of D 2 -like dopamine receptors Self et al., 1998) . Such observations are consistent with the in vitro cellular models previously described and support the hypothesis that chronic activation of G␣ i/ocoupled receptors by abused drugs in vivo induces heterologous sensitization of adenylate cyclase. Furthermore, cellular models of heterologous sensitization indicate that G␣ i/o -coupled receptor desensitization or tolerance is not responsible for sensitization (Watts and Neve, 1996; Thomas and Hoffman, 1987) . In support of in vitro models, Bohn et al. (2000) used a ␤-arrestin-2 knockout mouse model to demonstrate that opioid receptor desensitization and subsequent tolerance were not required for morphine-induced sensitization of adenylate cyclase. This study showed that ␤-arrestin-2-deficient (nondesensitizing) mice develop marked physical dependence, as measured by naloxone-precipitated withdrawal, but they did not develop tolerance to the antinociceptive effects of morphine. These findings are consistent with the hypothesized role of cAMP up-regulation in withdrawal following chronic drug abuse.
The mechanisms for the development and expression of heterologous sensitization following chronic treatment with drugs of abuse will vary across brain regions. For example, chronic morphine treatment increases adenylate cyclase activity in the locus coeruleus through an increase in the expression of AC1 and AC8 (Lane-Ladd et al., 1997) . Chronic morphine treatment also increases the activity and expression of PKA in the locus coeruleus (Lane-Ladd et al., 1997) . A consequence of drug removal would be that activation of the adenylate cyclase (AC1 and AC8) pathway would produce a dramatic increase in PKA-mediated signaling events when compared with drug naive animals. The effects of chronic opiate treatment on the cAMP-PKA pathway, however, would differ in brain areas with high expression of AC5, such as the nucleus accumbens, the ventral tegmental area, and the neostriatum (Lane-Ladd et al., 1997; Nestler and Aghajanian, 1997) . Because AC5 is negatively regulated by PKA (Taussig and Zimmerman, 1998) , a drug-induced increase in the expression of PKA would dampen the subsequent cAMP-PKA signaling in those particular brain regions. In addition to these examples, chronic opiate administration has also been shown to alter a number cellular signaling proteins that may directly and indirectly contribute to heterologous sensitization (Taylor and Fleming, 2001 ). These observations highlight the importance of identifying the components involved in heterologous sensitization in the elucidation of the molecular mechanisms in both in vitro and in vivo models.
Summary and Conclusions
Persistent activation of G␣ i/o -coupled receptors results in an enhanced response to drug-stimulated cAMP accumulation. This heterologous sensitization is a cellular adaptive response that occurs following the persistent activation of a number of G␣ i/o -coupled receptors including D 2 -like dopamine, M 2 and M 4 muscarinic, -, ␦-, and -opioid, CB 1 cannabinoid, A 1 and A 3 adenosine, ␣ 2 adrenergic, 5-hydroxytryptamine 1A serotonin, and somatostatin receptors. The characteristics of this enhanced responsiveness are dependent upon the cellular model used and may ultimately reflect the expression profile of adenylate cyclase isoforms and the agent used to stimulate cAMP accumulation.
The studies discussed in this article support the hypothesis that persistent activation of a G␣ i/o -coupled receptor promotes the dissociation of G␣ and ␤␥ subunits in a pertussis toxin-sensitive matter, which in turn, induces sensitization through a G␣ s -dependent mechanism (Fig. 2) . The signaling events that follow the activation of the G␣ i/o subunits and the release of the ␤␥ subunits are thought to produce an enhanced interaction between G␣ s and adenylate cyclase. These signaling events are still undefined but may lead to changes in the activity or the subcellular localization of G␣ s ). In this model, the pertussis toxin-sensitive events contribute to the development of heterologous sensitization, whereas the G␣ s -dependent events that regulate the isoforms of adenylate cyclase contribute to the expression of heterologous sensitization. The last 15 years of research have provided additional insight into the mechanisms involved in heterologous sensitization; however, the specific signaling events leading to G␣ s -dependent heterologous sensitization remain to be elucidated.
